You are here

Article Text

Article menu
Download PDFPDF
Letter
Unlicenced cannabis-based product use in adult palliative medicine
  1. Mark Howard and
  2. Jannah Harrison
  1. Department of Palliative Care, Saint Francis Hospice, Romford, London, UK
  1. Correspondence to Dr Mark Howard, Palliative Care, Saint Francis Hospice, Romford RM14QH, London, UK; markhoward{at}sfh.org.uk

https://doi.org/10.1136/bmjspcare-2021-003012

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Little is known about the prevalence of unlicenced cannabis-based product use in adult palliative care patients in the UK. Research in other jurisdictions where medicinal cannabis is legal has documented challenges with integration into clinical practice.1 The scheduling of these drugs in the UK changed in 2018.2 There remain few randomised controlled trials to support their use, which contributes to ongoing barriers to prescribing. At a hospice in London, we have been increasingly questioned by patients and families about the benefits of unlicenced forms of these products. Their usage appeared to be increasing in our geographical area. Anecdotally, they were …

    View Full Text

    Footnotes

    • Contributors MH was responsible for data collection, analysis and write up. JH was responsible for data collection and analysis.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.